Παρασκευή 4 Αυγούστου 2017

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Approximately 5% of unselected patients with breast cancer carry a germline BRCA mutation. Such mutations are more likely to be present in patients who have a strong family history of breast cancer, younger patients, patients who have triple-negative (i.e. human epidermal growth factor receptor…

http://ift.tt/2qRdC74

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου